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Abstract
The economic and health burden caused by adverse drug reactions has increased dramatically in the last few years. This is
likely to be mediated by increasing polypharmacy, which increases the likelihood for drug–drug interactions. Tools utilized
by healthcare practitioners to ﬂag potential adverse drug reactions secondary to drug–drug interactions ignore individual
genetic variation, which has the potential to markedly alter the severity of these interactions. To date there have been limited
published studies on impact of genetic variation on drug–drug interactions. In this review, we establish a detailed
classiﬁcation for pharmacokinetic drug–drug–gene interactions, and give examples from the literature that support this
approach. The increasing availability of real-world drug outcome data linked to genetic bioresources is likely to enable the
discovery of previously unrecognized, clinically important drug–drug–gene interactions.
Introduction
It was previously and alarmingly reported that adverse drug
reactions (ADRs) represent the fourth leading cause of death
in the USA [1]. A recent review (2015) showed that 3.6% of
patients were admitted to hospitals in Europe due to ADRs
and 10% of patients developed side effects during their in-
patient stay [2]. The latest report issued by MiDatabank in
cooperation with the Medicines and Healthcare Products
Regulatory Agency, shows an increasing trend in the number
of reported ADRs in the period between 2011 and 2016
across the UK [3]. It has also been estimated that ADRs alone
cost the NHS £770M annually [4]. Nonsteroidal antiin-
ﬂammatory drugs, diuretics, anticoagulants, and antiplatelets
have been recognized to be the major culprits, with pre-
scribing errors being major contributors to medication-related
adverse events [5]. The chance of these errors increases when
patients undergo multiple treatments; a situation that is highly
prevalent in elderly patients [6]. There are a number of factors
that inﬂuence the occurrence of ADRs secondary to
drug–drug interactions, such as age, renal function, and other
comorbidities. In addition, genetic variation is likely to play a
crucial role in the development of ADRs. For example, when
only considering genetic polymorphisms in three drug meta-
bolizing enzymes (cytochrome P450 2C9 (CYP2C9),
CYP2C19, and CYP2D6), 15% of the ADRs were due to
drug–gene interactions, and 19% were due to drug–drug–gene
interactions [7]. Incorporation of these gene variants increased
the number of predicted clinically critical drug interactions by
~51% [7]. Given the large number of genes involved in drug
metabolism and transport, we cannot underestimate the
importance of genetic variation in contributing to potential for
clinically critical ADRs.
Following the recent advances in pharmacogenomics, the
traditional view of drug–drug interactions needs to be
modiﬁed to include genetic variation. To date the literature
on drug–drug–gene interactions (DDGIs) is limited, with
only one previous review evaluating the impact of
CYP2C9, C19, and 2D6 variants [8]. In this review, we
attempt to provide an in-depth framework for the classiﬁ-
cation of pharmacokinetic DDGIs caused by different
mechanisms, and their potential impact to increase clinically
critical drug interactions in the context of the polypharmacy
seen in modern medicine today.
Drug–drug–gene interactions
DDGIs can be divided into three main categories: inhibitory
interactions, induction interactions, and phenoconversion
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interactions. Inhibitory and induction interactions can be
deﬁned as any interactions that affect the victim drug’s
pharmacokinetics (PK) to increase or reduce concentrations
of the drug, respectively. Induction or inhibition can occur
either with the administration of a perpetrator drug that
alters the victim drug metabolism or transport, or with the
presence of loss- or gain-of-function (LOF or GOF) genetic
variants that alter function of enzymes that alter metabolism
or transport of the victim drug, or the combination of both.
A DDGI can be thought of as a double hit—whereby the
genetic variant and the perpetrator drug combine to act on
transporter or metabolism pathways to greatly alter drug
concentrations. It is also possible to see phenoconversion—
where the interacting drug effect and the genotype have
opposing effects, resulting in a temporary phenotype shift
e.g. neutralizing/reversing the effect of a GOF genotype
when an inhibitory drug is prescribed. In this review we
describe, with examples, different cases of interactions
under each of the above three categories, focusing initially
on metabolizing enzymes, before considering drug
transporters.
Drug–drug-metabolizing enzyme gene interactions
(DDMEGIs)
Inhibitory interactions
Inhibitory effects of drugs and genotype can alter substrate
metabolism by both drug and genotype impacting on the
same metabolizing enzyme, or on two distinct routes of
metabolism.
In general, poor metabolizers are expected to experience
the highest substrate drug plasma concentration, compared
with other genotypes, when co-treated with inhibitors. For
example, co-administration of simvastatin (a CYP2C9
inhibitor) with warfarin (CYP2C9 substrate) has been
shown to reduce warfarin dosage requirements in
CYP2C9*3 carriers with a greater percentage as compared
with noncarriers (29% vs 5% respectively) [9]. A similar
conclusion has been reported with celecoxib (Supplemen-
tary Table 1) [10]. The inhibitory effect of drug and geno-
type is not always additive—genetically poor metabolizers
may have only limited further enzyme inhibition by
administration of an inhibitory drug. For instance, a statis-
tically signiﬁcant elevation in rabeprazole (a
CYP2C19 substrate) plasma levels was observed in both
normal metabolizers and heterozygous genotype carriers
after treatment with ﬂuvoxamine (a CYP2C19 inhibitor)
while no additional clinically signiﬁcant elevation was
detected with poor metabolizers who have already experi-
enced the highest rabeprazole plasma levels [11]. A similar
scenario is seen with other examples (Supplementary
Table 1) [12–15].
Where a drug is metabolized by two or more CYP
enzymes, then inhibition of one of these enzymes alone (by
drug or genotype) may have minimal effect, due to redun-
dancy of the pathways. However, if a genotype and inter-
acting drug affect these different routes of metabolism, then
the interaction may be very large. For example, it has been
observed that for voriconazole (a CYP2C19 and
CYP3A4 substrate) bioavailability is increased markedly
(~5.6-fold) in patients who have reduced CYP2C19 activity
and are administered with atazanavir or ritonavir (potent
CYP3A4 inhibitors) [16]. A similar scenario can be noted
with other examples (Supplementary Table 1) [17–19].
Prodrugs, on the other hand, require the function of
certain CYPs to be therapeutically active, and in these cases
the effect is the opposite to that described above. Clopi-
dogrel, for example, is activated by CYP1A2, CYP2B6,
CYP3A4, CYP2C9, and CYP2C19 [20]. Carriers of LOF
variants in one or more of these genes and co-administered
with their inhibitors are at increased risk for treatment
resistance. For instance, carriers of CYP2C19*2 and/or *3
alleles who are treated with clopidogrel and proton pump
inhibitors (CYP2C19 inhibitors) were observed to be more
likely to have reduced clopidogrel efﬁcacy; the addition of a
third risk factor (e.g., calcium channel blockers (CYP3A4
inhibitors)) was also correlated with a greater reduction in
efﬁcacy of clopidogrel [21, 22].
Figure 1 shows the predicted changes of plasma levels of
active drugs and active metabolites of prodrugs with and
without the presence of inhibitors and/or LOF variants.
Induction interactions
Increased metabolism of active drugs by an enzyme inducer
or GOF variant will result in reduced efﬁcacy of the victim
drug. For example, when voriconazole (a
CYP2C19 substrate) is co-prescribed with carbamazepine
(CYP2C19 inducer) the voriconazole dose is usually
increased to overcome this increased metabolism. In a case
report, therapeutic concentrations of voriconazole were not
achieved, as the patient carried two GOF CYP2C19 *17
variants [23].
The opposite effect is seen with prodrugs. Increased
metabolism by an enzyme inducing drug or GOF variant,
will result in high plasma levels of active metabolites
leading to increased side effects and/or efﬁcacy. Thus,
patients carrying CYP2C19*17 GOF variants have
increased conversion of clopidogrel to active metabolites
resulting in reduced cardiovascular events and/or increased
bleeding episodes [24–33]. Co-administration of an inducer
of CYP1A2, CYP2C9, and/or CYP3A4 would be expected
to result in greater efﬁcacy of clopidogrel, with increased
risk of bleeding, however no studies have been published to
establish this.
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Figure 2 shows the predicted changes of plasma levels of
active drugs and active metabolites of prodrugs with and
without the presence of inducers and/or GOF variants.
Phenoconversion interactions
As described above, a temporary phenotype shift can be
seen when the perpetrator drug and genetic effect are
opposed. For example, the presence of reduced function
CYP2C9 variants results in reduced tolbutamide (a
CYP2C9 substrate) metabolism, yet co-treatment with
rifampicin (a CYP2C9 inducer) in these patients reverses
this genetic effect resulting in a twofold increase in tolbu-
tamide clearance [34]. Conversely, proton pump inhibitors
(CYP2C19 inhibitors) treatment with clopidogrel results in
phenoconversion in genetically determined ultra-rapid
phenotype to a poor metabolizer status indicated by loss
of clopidogrel efﬁcacy [35].
The beneﬁcial side of phenoconversion interactions is that
genetically determined phenotypes can be normalized by the
addition of medications of opposite effects on metabolism.
For example, resistance to nortriptyline (CYP2D6 substrate)
due to abnormally rapid metabolism has been successfully
reversed and normalized with the addition of paroxetine a
(CYP2D6 inhibitor), which produces a recovery of nor-
triptyline therapeutic plasma levels [36].
Figure 3 presents different scenarios of phenoconversion
interactions.
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Fig. 1 The predicted active drug/
active metabolites of prodrugs
plasma levels and biliary
excretion changes without or
with the presence of inhibitors or
LOF variants or both on
metabolizing enzymes. The
predicted active drug/active
metabolites of prodrugs plasma
levels and biliary excretion
changes without (a-1/a-2) or
with the presence of inhibitors or
LOF variants (b-1/b-2) or both
(c-1/c-2) on metabolizing
enzymes. a-1/a-2 represent the
normal scenario with no
interacting drug or genetic
variant. In b-1/b-2 either an
inhibitory drug or loss-of-
function variant (LOF) in the
metabolizing enzyme, results in
reduced metabolism to inactive
metabolites, and increased (b-1)/
decreased (b-2) active drug in
the systemic circulation. In c-1/
c-2 the presence of inhibitory
drug and the LOF genetic
variant combine to produce
greater increase (c-1)/decrease
(c-2) in the systemic
concentration of active drug
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Drug–drug-transporters genes interactions (DDTGIs)
Drug transporters govern the movement of pharmaceutical
compounds from and into different body tissues. The liver,
kidney, blood–brain barrier (BBB), and intestine are the key
sites of transporters that inﬂuence drug PK. In addition to
summarizing the distribution and localization of transpor-
ters, Fig. 4 also classiﬁes transporters into three categories
according to the similarity of transport directions in differ-
ent tissue types (the ﬁgure has been formulated with the aid
of reference [37]). Drug–drug–gene interactions for trans-
porters are less well studied than for metabolizing enzymes.
For each subgroup, Drug Transporter-gene interaction
(DTGI) studies will be utilized (if no direct DDTGI studies
are available) to illustrate each mechanism for potential
interaction. Similar to the drug metabolizing enzyme sce-
narios outlined above, we predict that these interactions
may be intensiﬁed or reversed, via inhibitory/induction or
phenoconversion pathways, with the co-administration of
inhibitors or inducers.
Efﬂux transporters
Efﬂux transporters have been classiﬁed into two groups
(group I and group II) according to the similarity in the
transport directions.
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Fig. 2 The predicted active drug/
active metabolites of prodrugs
plasma levels and biliary
excretion changes with out or
with the presence of inducers or
GOF variants or both on
metabolizing enzymes. The
predicted active drug/active
metabolites of prodrugs plasma
levels and biliary excretion
changes without (a-1/a-2) or
with the presence of inducers or
GOF variants (b-1/b-2) or both
(c-1/c-2) on metabolizing
enzymes. a-1/a-2 represent the
normal scenario with no
interacting drug or genetic
variant. In b-1/b-2 either an
inducer drug or gain-of-function
variant (GOF) in the
metabolizing enzyme, results in
increased metabolism to inactive
metabolites, and decreased (b-
1)/increased (b-2) active drug in
the systemic circulation. In c-1/
c-2 the presence of inducer drug
and the GOF genetic variant
combine to produce greater
decrease(c-1)/increase(c-2) in
the systemic concentration of
active drug
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Group I P-glycoprotein 1 (P-gp, ABCB1), multidrug
resistance-associated protein 2 (MRP2, ABCC2), and breast
cancer resistant protein (BCRP, ABCG2) transporters are
expressed in the intestine, liver, kidney, and BBB, sharing
similar transport pathways. They efﬂux substrates back to
intestinal lumen, facilitate hepatic and renal excretion
(excluding BCRP), and work inversely in the BBB where
they protect the brain from the entry of xenobiotics and
return them back to systemic circulation. Blocking their
function in the intestine, liver, or kidney is expected to
elevate a substrate’s systemic exposure (although opposite
effects would be predicted if inhibiting transport across
the BBB).
In this group, the most evidence for DDTGI comes from
drugs altering ABCB1 (P-gp) transport and genetic variants
in the gene encoding this transporter. For example,
cyclosporine is an ABCB1 substrate. Diltiazem (a moderate
ABCB1 inhibitor [38]) has been shown to increase
cyclosporin trough concentrations in Chinese patients who
carry the TT genotype (low P-gp activity) at rs1045642
(C>T) in ABCB1; yet no effect was seen in other ABCB1
genotypes (e.g., CC at rs1045642) [39]. Methadone is also a
P-gp substrate, acting in the brain and efﬂuxed across the
BBB via P-gp. Patients with the TT genotype at rs1045642
and treated with quetiapine (ABCB1 inhibitor) experienced
the lowest increase in methadone plasma levels compared
with those with CT or CC genotypes (3% vs 23% vs 33%
respectively) [40]. Low methadone plasma levels in this
study would be explained by loss of the ABCB1 protective
function in the BBB which results in increased intracerebral
concentration of this central nervous system (CNS) drug. As
a result of a similar DDTGI mechanism, the CNS drug
granisetron was associated with increased efﬁcacy in
Japanese subjects (Supplementary Table 1) [41].
In some cases, it seems that adding strong inhibitors
abolishes the effect of genotype. For example, no additional
inhibitory effects were detected in carriers of different
genotypes of the rs1045642 (C>T) ABCB1 variant who
were either on dabigatran/rivaroxaban-clarithromycin com-
bination or tacrolimus-itraconazole combination (ABCB1
substrates-ABCB1 strong inhibitors [38]) [42, 43].
ABCC2 and ABCG2 would be predicted to follow similar
interaction scenarios as ABCB1, yet we were unable to ﬁnd
any studies that report DDTGIs for these transporters.
Group II Unlike group I transporters, there are no pub-
lished studies describing DDTGIs for group II transporters.
So here we report DGTIs to highlight the potential
mechanisms whereby genes and drugs that alter these
transporters may inﬂuence drug outcomes. MRP1(ABCC1),
MRP3 (ABCC3), and MRP4(ABCC4) share the similar
transport direction in the kidney and BBB as the Group I
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transporters. However, in the liver, they are expressed in the
basolateral membrane working to pump drugs back into
systemic circulation. MRP1, for example, transports the
active metabolite of irinotecan (SN-38) out of hepatocytes
into the blood contributing to the well-known side effect of
irinotecan induced neutropenia [44]. The reduced function
variant, rs17501331, in the ABCC1 gene is associated with
low incidence of neutropenia; the reverse effect was
detected with the GOF variant rs6498588 in the same gene
[45]. In some cases, increased activity of the MRP1 trans-
porter can be advantageous, as seen with methotrexate
hepatotoxicity where carriers of wild-type genotype of
ABCC1 rs246240 (A>G) variant are at higher risk for
developing methotrexate toxicity compared with carriers of
reduced function alleles [46]. Of note, MRP1 is also
expressed in the myocardium protecting the heart from the
entry of xenobiotics [47]. For example, the reduced trans-
port associated with the rs45511401 (G>T) in ABCC1
increases the chance of developing cardiotoxicity due to
intracellular accumulation of doxorubicin [48]. MRP1 and
MRP3, in contrast to P-gp, MRP2 and BCRP, are expressed
in the basolateral membrane of the intestine efﬂuxing sub-
strates into the portal circulation. As orally administered
drugs are ﬁrst exposed to intestinal transporters, any mod-
iﬁcation of their role might affect drug concentration in the
other tissues (liver, kidney, or BBB). C.1037 C>T and
c.1820G>A ABCC3 variants, for example, have low
transport activity [49] suggesting their potential to diminish
the bioavailability of oral MRP3 substrates irrespective of
subsequent alteration in transport into other tissues, or
subsequent metabolism.
Uptake Transporters (Group III)
In the liver, kidney, and BBB, all important uptake trans-
porters (organic cation transporters (OCTs)1/2/3, organic
anion-transporting polypeptide (OATP) 1B1/1B3/2B1, and
multidrug and toxic compound extrusion proteins (MATE)
1/2), follow an identical main route for transporting their
substrates: from systemic circulation into different tissues or
urine/bile in case of MATEs. Consequently, reducing or
increasing these transport capacities would result in
increased or reduced systemic drug concentrations respec-
tively. The reverse effects are seen with the uptake trans-
porters expressed in the intestinal apical membrane such as
OATPs and OCT1 since the transportation pathway is in the
opposite direction.
In some circumstances, altering uptake transporter
function can increase ADRs. For example, it has been
observed that carriers of two OCT1 (SLC22A1) reduced
function alleles who were treated with OCT1 inhibitors
were over four times more likely to develop gastrointestinal
side effects with metformin (an OCT1 substrate) treatment,
which would be attributable to metformin accumulation in
the intestinal lumen (assuming apical OCT1 localization)
[50]. This ﬁnding was supported by a previous study [51].
At the level of renal uptake transporters, other DDTGIs
have been reported in which carrying the mutant alleles and
the co-administration of inhibitors was linked to increased
metformin plasma levels/toxicity or reduced clearance (see
Supplementary Table 1) [52, 53]. By contrast, reducing
transport in some cases may reduce certain side effects. For
instance, cisplatin (a OCT2 (SLC22A2) substrate) is both a
nephrotoxic and an ototoxic agent. People carrying the
rs316019 (C>A) OCT2 mutation were protected from these
adverse reactions as the variant resulted in reduced transport
of cisplatin into the kidney and the inner ear (cochlea)
(where OCT2 is expressed as well) [54–56].
In many situations, the efﬁcacy of a drug relies upon the
ability of that drug to access certain tissues. Statins are
taken up into the liver by OATP1B1(SLCO1B1) and this is
crucial for their lipid lowering effect. Reducing this uptake
pathway reduces statin efﬁcacy and raises plasma con-
centrations, resulting in myopathy and, rarely, rhabdo-
myolysis. The rs4149056 (T>C) (SLCO1B1*15) variant
has been widely studied, and in 23 studies [57–79], this
variant has been persistently connected to increased statin
plasma exposure, muscle aches, dose reduction, and/or
treatment-resistant phenotypes. A number of other DDGIs
have been described for the SLCO1B1 transporter.
For example, although the increase in pravastatin
(SLCO1B1 substrate) AUC after treatment with ritonavir
(SLCO1B1 inhibitor) was not statistically signiﬁcant (21%
increase vs pravastatin alone) a large interaction was seen in
those carrying the SLCO1B1*15 or *17 haplotypes, with a
resulting 113% elevation in pravastatin AUC [80]. Other
DDTGIs with the similar mechanism have also been pub-
lished (see Supplementary Table 1) [81–83]. Interestingly,
unlike the ritonavir example just outlined, in some situa-
tions reduced function variants do not show any signiﬁcant
PK change until after the addition of inhibitors. For exam-
ple, patients with AG or AA genotypes at rs2289669(G>A)
of the MATE1 transporter only had signiﬁcantly lower
metformin (MATE1 substrate) clearance compared with
carriers of GG genotype after treatment with ranitidine (a
MATE1 inhibitor) [84].
DDGIs and challenges in clinical practice
Metabolizing enzyme and transporter substrates, inducers,
or inhibitors are not fully documented in many popular drug
interaction databases, leaving physicians unaware of
potentially important interactions. In addition, most of the
resources commonly used by prescribers (e.g., Stockley’s,
Micromedex, Drug.com, RxList, or other drug interaction
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checkers) do not consider genetic variation when classifying
drug interactions into minor, moderate, or major classes.
Genetic variation may markedly increase or ameliorate the
severity of potential drug interactions and do need to be
considered when considering real-world use of drugs.
This review has discussed the different mechanisms of
interactions in their simplest forms with the assumption that
the patient is free of transporter polymorphisms or inhibitors/
inducers in the case of discussing DDMEGIs and vice versa
with DDTGIs. However, in real-world clinical practice,
achieving precisely tailored drug therapy requires a detailed
examination of all mutations in the candidate enzyme or
transporter genes with good awareness of the entire prescribed
medications and possible pathways of interaction. Thus, the
clinical scenario ranges from a relatively simple picture where
the effect of genotype and interacting drug(s) can be
approximated and treatment altered accordingly, to a far more
complex scenario where physiologically based PK (PBPK)
modeling may be helpful and where evaluation of large scale
clinical data linked to genotypes is required to evaluate the
clinical impact of multiple interacting drugs/multiple geno-
types on drug outcomes.
Consider a relatively simple scenario: a patient with type 2
diabetes treated with metformin (has no effect on CYPs) who
carries reduced function variants in CYP2C9 (*2 or *3 var-
iants) and who is started on gliclazide (CYP2C9/19 substrate).
Reduced metabolism of gliclazide will result in increased
efﬁcacy [85] and increased risk of hypoglycemia [86]. The
metformin use will not alter this DGI. However, if this patient
were also treated with pioglitazone and/or atorvastatin (both
are CYP2C9/19 inhibitors) they would be at potentially even
greater risk of gliclazide-induced hypoglycemia and should be
treated with a reduced dose of gliclazide. However, even for
this simple scenario, such DDGI studies have not been
reported; nor have dosing algorithms been developed to date
for patients with CYP2C9 variants prescribed sulphonylureas
and as such it is difﬁcult to implement this into drug inter-
action calculators.
There are many more complex scenarios where, for
example, a combination of both metabolizing enzyme and
transporter LOF/GOF variants, as well as inhibitors/indu-
cers are included. This kind of interaction may be only
initially predictable when all their subinteractions result in
the same clinical effect. For instance, reduced CYP3A4 and
SLCO1B1 activities can both result in increased AUC of the
substrate drug and a greater harm would be anticipated.
Carriers of the TC genotype of SLCO1B1 rs4149056 (T>C)
variant who are treated with amlodipine (CYP3A4 inhi-
bitor) experienced a 90% increased simvastatin AUC
compared with subjects not treated with amlodipine and
wild-type for rs4149056 [87]. A similar scenario was
reported with other two case reports (see Supplementary
Table 1) [88, 89].
In other situations, subinteractions do not share a similar
clinical effect. Here, predicting the overall clinical outcome
is challenging. As an illustration, oral rosuvastatin is mainly
eliminated via biliary excretion with a minor contribution of
CYP2C9 to its metabolism [90]. This implies that its
transporters (e.g., ABCC2, ABCG2, ABCC1, and
SLCO1B1) are the core players in its elimination. The
concomitant administration of verapamil (an ABCC1/2
inhibitor) and venlafaxine (an ABCG2 inducer) in those
who have inherited CYP2C9*3 and/or SLCO1B1
rs4149056 (T>C) LOF variants results in unpredictable
clinical consequences. CYP2C9, SLCO1B1, and ABCC2
impairment would boost rosuvastatin AUC, inducing
ABCG2 would lower rosuvastatin AUC, and inhibition of
ABCC1 could result in both increase or decrease in AUC
(high AUC if the site of interaction is in the kidney and low
AUC if it is in the intestine or liver). The exact estimation of
the predicted net AUC following a certain DDGI relies on
calculating the contribution of each metabolizing enzyme
and transporter to the elimination process (i.e. degree of
sensitivity of substrates), inhibition/induction potency of the
perpetrator agent or the net effect of multiple inhibitors,
inducers, or both, and the net percentage of reduction/ele-
vation in the enzyme/s and/or transporter/s activity caused
by a single or more SNPs. The outcome of such a hugely
complex scenario is impossible to predict by the clinician,
and requires a clinical support tool based upon a PK DDGI
prediction algorithm. Most of the current work concentrates
on generating either DD or DG interaction predictors rather
than the combined effect of both drugs and variants.
However, using PBPK models, one predictor tool
(https://www.ddi-predictor.org/) has recently been success-
fully generated to estimate drug exposure and the recom-
mended dose following the dual action of both the
perpetrator drug and mutations in certain CYPs (CYP2D6,
CYP2C9, and CYP2C19) [91]. Other PBPK models do
attempt to incorporate genotype and drug–drug interactions,
but these do not model transporter variants well and have
yet to translate through into clinically useful tools [92].
An alternative method to evaluate the impact of DDGIs
is via metabolizing enzymes and transporters endogenous
biomarkers rather than plasma concentrations of substrate
drugs. Multiple enzymes/transporters-related biomarkers
have been identiﬁed [93]. For instance, it has been shown
that the cholesterol, cortisone, and cortisol metabolites:
4β-hydroxycholestrol,6β-hydroxycortisone, and 6β-
hydroxycortisole, respectively, which are catalyzed by
CYP3A4 activity, are increased under the effect of indu-
cers and decreased with inhibitors of CYP3A4. It was also
recognized that bufotenine is a major metabolite resulting
from the metabolizing activity of CYP2D6. With regard
of transporters, several studies have observed the asso-
ciation between increased bilirubin plasma levels and
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reduced hepatic OATP1B1/1B3 uptake function. The
similar scenario was noted recently with the novel bio-
markers coproporphyrins I and III (CPs I and III) where
plasma CPs levels elevated with the inhibition of these
transporters to a similar extent as with rosuvastatin. In
DDGIs studies, endogenous biomarkers can be utilized to
predict the effect of both genetic variants and inhibitors/
inducers on the substrate drugs plasma levels.
It is worth noting that potential DDIs do not necessarily
reﬂect actual interactions. It has been observed that clini-
cally signiﬁcant interactions are consistently lower than
theoretically predictable interactions [94]. However, the
authors noted that 20% of ADRs are linked with DDIs; most
of them are serious with a high percentage of fatal cases.
They also concluded that therapeutic failure secondary to
DDIs, which is usually underestimated, represents a con-
siderable part of total DDIs-related undesirable effects. The
degree of clinical signiﬁcance can be judged by observing
other risk factors associated with a potential DDI such as
polypharmacy and genetic variants. Polypharmacy is com-
monly seen with elderly and hospitalized patients making
them the most vulnerable patient’s subgroups to clinically
signiﬁcant interactions besides carriers of risky genetic
variants. In addition, not all types of DDGIs are expected to
be common. Induction and phenoconversion DDGIs are
predicted to be seen with lower incidence compared with
inhibitory DDGIs as the majority of perpetrator drugs are
inhibitors rather than inducers and most of functional
genetic variants are loss rather than GOF mutations.
The increasing availability of ‘big data’ linking health
data and genomics has the potential to evaluate the real-
world clinical impact of multiple drugs/multiple variant
interactions. A number of data sets are now available or
about to become available for study. In Scotland national
prescribing and linked outcomes are available for the entire
population enabling evaluation of real-world DDIs, and
with an increasing bioresource (https://www.registerforsha
re.org) it should be possible to evaluate DDGIs in ~500 K
people over the next few years. In addition, other resources
such as UK biobank including genetic information on 500 K
individuals (with primary care data available on 200 k
during 2018) and other national bioresources (such as the
Danish biorepository) and US bioresources linked to EHRs
(EMERGE network) will enable the evaluation of n-way
DDG interactions to identify clinically important interac-
tions that can be incorporated into clinical decision support
tools in the future.
Conclusion
Dozens of new pharmaceutical compounds enter the market
each year and a considerable number of patients are
prescribed multiple drugs that necessitate the utilization of
drug interaction databases for better management. One of
the major limitations of these drug interaction checkers is
the omission of the genetic effect on drug interactions. This
reﬂects both the lack of clinical studies that quantity
potential DDGIs and the fact that genetic information is
rarely available on patients at the point of prescribing. This
review has illustrated, with some examples, various
mechanisms by which DDGIs can occur at the level of
metabolizing enzymes, drug transporters, or both (this has
been summarized in Supplementary Table 1). We have also
shown the different degrees of complexity clinicians may
face in judging the predicted clinical outcome following a
certain DDGI. The more factors that are included, the more
challenging it becomes to evaluate the outcome. There is a
need for PBPK models, clinical studies and real-world
evaluation of drug outcomes linked to genetic information
to develop clinical useful DDGI models, to reduce adverse
DDIs and improve drug outcomes in the setting of
increasing multi-morbidity and polypharmacy.
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